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Subchondral pre-solidified chitosan/blood
implants elicit reproducible early osteochondral
wound-repair responses including neutrophil and
stromal cell chemotaxis, bone resorption and
repair, enhanced repair tissue integration and
delayed matrix deposition
Charles-Hubert Lafantaisie-Favreau1, Jessica Guzmán-Morales2, Jun Sun3,4, Gaoping Chen2, Adam Harris2,
Thomas D Smith2, Alberto Carli5, Janet Henderson5, William D Stanish6 and Caroline D Hoemann1,2*
Abstract
Background: In this study we evaluated a novel approach to guide the bone marrow-driven articular cartilage
repair response in skeletally aged rabbits. We hypothesized that dispersed chitosan particles implanted close to the
bone marrow degrade in situ in a molecular mass-dependent manner, and attract more stromal cells to the site in
aged rabbits compared to the blood clot in untreated controls.
Methods: Three microdrill hole defects, 1.4 mm diameter and 2 mm deep, were created in both knee trochlea of
30 month-old New Zealand White rabbits. Each of 3 isotonic chitosan solutions (150, 40, 10 kDa, 80% degree of
deaceylation, with fluorescent chitosan tracer) was mixed with autologous rabbit whole blood, clotted with Tissue
Factor to form cylindrical implants, and press-fit in drill holes in the left knee while contralateral holes received
Tissue Factor or no treatment. At day 1 or day 21 post-operative, defects were analyzed by micro-computed
tomography, histomorphometry and stereology for bone and soft tissue repair.
Results: All 3 implants filled the top of defects at day 1 and were partly degraded in situ at 21 days post-operative.
All implants attracted neutrophils, osteoclasts and abundant bone marrow-derived stromal cells, stimulated bone
resorption followed by new woven bone repair (bone remodeling) and promoted repair tissue-bone integration.
150 kDa chitosan implant was less degraded, and elicited more apoptotic neutrophils and bone resorption than 10
kDa chitosan implant. Drilled controls elicited a poorly integrated fibrous or fibrocartilaginous tissue.
Conclusions: Pre-solidified implants elicit stromal cells and vigorous bone plate remodeling through a phase involving
neutrophil chemotaxis. Pre-solidified chitosan implants are tunable by molecular mass, and could be beneficial for
augmented marrow stimulation therapy if the recruited stromal cells can progress to bone and cartilage repair.
Keywords: Cartilage repair, Bone marrow, Chitosan, Osteoclast, Neutrophil, Collagen, Marrow stimulation, Bone
remodeling, Mesenchymal stromal cell, Micro-computed tomography
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Marrow stimulation is a cartilage repair technique in which
bone channels are created at the base of the debrided car-
tilage lesion, to permit migration of bone marrow-derived
repair cells into the lesion. Marrow stimulation techniques
most often elicit fibrous or fibrocartilaginous tissue [1] that
breaks down with time, with a documented ~25% failure
rate at 5 years post-operative [2]. Therefore, implants that
elicit a more hyaline repair tissue quality from marrow
stimulation defects are currently under intense research.
In designing new treatments to regenerate articular
cartilage, biomaterials that do not need to be seeded
with cultured cells have the advantage of being clinically
practical and cost-efficient. However, to be effective,
biomaterial-only implants must be able to guide mesen-
chymal stem cells with chondrogenic potential from the
bone marrow to above the osteochondral junction and
into the cartilage lesion. Biomaterials have previously been
successfully implanted into osteochondral defects, but re-
producible long-term clinical benefits have yet to be
demonstrated. A tubular implant composed of electrospun
poly(D,L-lactide-co-glycolide) (PLG) inserted in large
(5 mm wide, 5 mm deep) osteochondral defects in a rabbit
model generated good cartilage repair in most defects at
24 weeks post-operative [3]. Subchondral implants made
of PLG copolymer, calcium sulfate, polyglycolide fibers
and surfactant have demonstrated clinical benefit, with
complete pain alleviation and resumption of functional ac-
tivity after 24 months of continued rehabilitation in a case
study [4]; although other studies reported that PLG
persists and inhibits subchondral bone regeneration 6 to
12 months post-operative [5,6]. In a rabbit model, filling
the drill hole with a chemically cross-linked chitosan
hydrogel was previously shown to block cell infiltration
and bone repair [7]. Altogether, these data suggest that
the porosity and degradation kinetics of biomaterials
implanted in subchondral bone are key elements in the
induction of reproducible osteochondral repair.
It was previously shown that hybrid chitosan/blood
implants solidified in situ over the surface of microfracture
or microdrill defects elicit a more hyaline repair compared
to marrow stimulation alone [8,9]. The chitosan used to
generate these implants was biodegradable with ~80% de-
gree of deacetylation (DDA) and a molecular weight of
~100-250 kDa. The mechanisms of action were shown in a
rabbit model to implicate the sequential attraction of
neutrophils, osteoclasts and blood vessels, along with
enhanced subchondral bone remodeling, repair tissue inte-
gration and delayed chondrogenesis in repairing microdrill
holes [9-12]. The cartilage repair response, however, was
attenuated in aged rabbits [10], which parallels the reduced
efficacy of marrow stimulation therapies in patients over
40 years old [13,14]. A new approach is thus needed to re-
producibly elicit hyaline repair in older patients treated bymicrofracture. Rabbits are widely used as an in vivo carti-
lage repair model, which provides an abundant base of li-
terature for data comparison, and the use of aged rabbits
in a cartilage repair model could be useful in translating
new implants for augmented microfracture to treatments
for older subjects.
We hypothesized that chitosan/blood implants placed
directly in the marrow stimulation subchondral bone
channel of skeletally aged rabbits could attract more
bone marrow stromal cells than drilled control defects.
We also hypothesized that subchondral chitosan/blood
implants would be cleared with kinetics similar to a
blood clot and, compared to drilled control defects,
would attract more wound repair cells (neutrophils and
marrow-derived stromal cells) in a molecular weight-
dependent manner. Implants were delivered to drilled
subchondral defects to avoid bone compaction and
osteocyte death induced by microfracture [15]. In addition,
our study was designed to track tissue reactions of three
implant formulations with distinct chitosan molecular
weight in 3 drill holes per knee trochlea. The generation of
three structurally distinct fluorescent chitosan tracers with
the same rhodamine derivatization level (1 tag per 200
monomers) [16] is an innovation that permitted compara-
tive monitoring of the chitosan particle fate after 1-day and
3-weeks of in vivo repair. This formulation screening ex-
periment will thus allow the identification of the optimal
chitosan molecular weight to be used for subchondral im-
plantation in subsequent studies.
Methods
Study design
Three osteochondral drill holes were created bilaterally in
the knee trochlea of 30-month old New Zealand White
rabbits. In one knee, the 3 holes were press-fit with 3 dis-
tinct pre-solidified chitosan-NaCl/blood implants containing
chitosan (either high, low or ultra-low molecular weight,
inserted in the proximal, middle, and distal holes, respec-
tively). The 3 drill holes created in the contralateral con-
trol trochlea were left to bleed as surgical controls or
each drill hole treated with the same dose of Tissue Fac-
tor used to pre-solidify the chitosan/blood implants. Indi-
vidual drill holes (30 total holes) and associated repair
tissues were analyzed after 1 day (N=1 rabbits) or 21
days (N=4 rabbits) post-operatively by micro-computed
tomography to analyze residual bone defect size, and by
histology and histomorphometry to assess implant resi-
dency, cell recruitment, matrix deposition, evidence of
new bone formation, and repair tissue integration.
Materials and chitosan characterization
High molecular weight chitosans (80% - 82% degree of
deacetylation, DDA, endotoxins <500 EU/g, <0.2% pro-
tein, <5ppm heavy metals, <0.2% ash) were obtained
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Healthcare), from which 81.9% DDA chitosan was
depolymerized by nitrous acid as previously described [17]
to a targeted number-average molecular weight (Mn) of
~40 kDa, and ~10 kDa, respectively (Table 1, 40K and
10K, and 150K). Nitrous acid cleaves the β–O-(1–4)
glycosidic linkages without affecting the N-acetyl groups
[18], and the DDA of the depolymerized chitosan was
assumed to be identical to the DDA of the parent chitosan
(Table 1). Free-base chitosan powders were dissolved at 20
mg/mL in dilute HCl overnight, then autoclave sterilized
and characterized for solution pH, osmolality, and
chitosan molecular weight (Mw) [16] (Table 1). Chitosan
Mw, Mn and polydispersity index (PDI, Mw/Mn) was
determined by size-exclusion chromatography with a Gel
Permeation Chromatography System, coupled with a
Dawn HELEOS II multiangle laser light scattering de-
tector (Wyatt Technology Co., Santa Barbara, CA, USA),
a Viscostar II (Wyatt Technology Co., Santa Barbara, CA,
USA), an Optilab rEX interferometric refractometer
(Wyatt Technology Co., Santa Barbara, CA, USA), and
two Shodex OHpak columns (SB-806M HQ and SB-805
HQ) connected in series, as previously described [19].
Chitosan was dissolved at 1 mg/mL in running buffer (pH
4.5 acetic acid, 0.15 M/sodium acetate, 0.1 M) and filtered
through a 0.45 μm membrane prior to the analysis.
Rhodamine B isothiocyanate (RITC) labelled chitosans
were generated from 3 structurally matched chitosans as
described [16], precipitated in free-base form, dissolved
in dilute HCl at 5 mg/mL and 90% protonation, 0.22 μm
filter-sterilized, and the derivatization level determined by
OD540 against a standard curve of rhodamine B (Table 1).
All liquid chitosan aliquots were stored at −80°C and
thawed once prior to use.
Recombinant human Tissue Factor with phospholipids
(InnovinW, Dade-Behring, Cedarlane, Mississauga, ON,
Canada) was reconstituted with 2 mL water for injection
(Abbott Laboratories, Dallas, TX, USA) at 5-times theTable 1 Chitosans and chitosan solutions used in this study
Chitosan DDA (%) Mw (kDa)
High (150K) Powder* 81.8 274.6
High (150K) Solution** 81.8 124.2
RITC-150K *** 80.6 246.4
Low (40K) Powder* 81.9 47.7
Low (40K) Solution** 81.9 31.6
RITC-40K *** 80.6 61.5
Ultralow (10K) Powder* 81.9 22.8
Ultralow (10K) Solution** 81.9 23.8
RITC-10K *** 80.0 22.4
* Chitosan powder used to make the 20 mg/mL autoclave-sterilized solution; ** Autoc
mg/mL filter-sterilized solution; DDA: Degree of deacetylation; Mw: Weight-average mo
(Mw/Mn); Osm: Osmolality; chi: chitosan.normal recommended concentration and stored at 4°C.
Microman M100 tips and microman pipettors were from
Gilson, Inc. (Middleton, MI, USA). Recombinant human
Factor VIIa (rhFVIIa, Novo Nordisk, Copenhagen, Den-
mark) was reconstituted at 500 μg/mL in water for injec-
tion and stored as aliquots at −80°C.
Implant optimization and rabbit surgical model
All procedures involving animals, including a specific
protocol for experimental procedures with aged rabbits,
were approved by institutional ethics review boards. For
in vitro optimization studies, isotonic chitosan solutions
[1.6% w/v chitosan-150 mM NaCl or 1.6% w/v chitosan-
100 mM disodium β-glycerol phosphate (GP)] were made
from distinct 2% w/v chitosan solutions and laced with
0.05% w/v RITC-chitosan of matching molecular mass
(Table 1). Formulations were mixed with rabbit peripheral
whole blood from anesthetised rabbits at a 1:3 or 1:6 v/v
chitosan:blood ratio in flat-bottom 2.0 mL cryovials
containing three sterile 0.39 g surgical steel mixing beads
(Salem Specialty Ball Company, Canton, CT, USA), and
shaken manually for 10 seconds. Liquid mixtures were so-
lidified in glass tubes with an inner diameter of 2.0 mm at
37°C for 30 minutes or at room temperature for 5 to 30
minutes in plastic syringes or microman tips with the
tapered end cut off using rhFVIIa or Tissue Factor to acce-
lerate coagulation. The macroscopic properties of the so-
lidified implants (shape, elasticity, serum extruded) were
determined visually and by manual assessment. The distri-
bution of fluorescent chitosan particles in implants pre-
solidified in glass tubes was documented by epifluorescence
microscopy. Implants with 1:6 v/v ratio chitosan-NaCl
/blood were selected for further analysis in vivo based on a
more rapid coagulation than chitosan-GP/blood, and
homogeneous dispersion of chitosan particles.
Five skeletally aged New Zealand White rabbits
(2.5 years old, 3 male, 2 female, mean 4.68±0.44 kg,
Charles River, St-Constant, QC, Canada), were housedMn (kDa) PDI Characteristics
241.2 1.1
107.4 1.2 pH=3.10 Osm=48mosm
176 1.4 0.50% mol/mol RITC/chi
37.3 1.3
25.3 1.2 pH=1.65 Osm=72mosm
46.7 1.3 0.52% mol/mol RITC/chi
10.3 2.2
12.7 1.9 pH=5.58 Osm=48mosm
12.4 1.8 0.58% mol/mol RITC/chi
laved 20 mg/mL chitosan solution; *** RITC-chitosan powder used to make the 5
lecular weight; Mn: Number-average molecular weight; PDI: Polydispersity index
Lafantaisie-Favreau et al. BMC Musculoskeletal Disorders 2013, 14:27 Page 4 of 16
http://www.biomedcentral.com/1471-2474/14/27individually in cages at controlled room temperature and
light cycle with ad libitum standard commercial rabbit
chow and municipal tap water available, and acclimatized
for at least 2 weeks prior to surgery. The rabbits were
anaesthetized with ketamine-xylazine-buprenorphine, had
their knees shaved and disinfected and were kept under
anaesthesia with 3% isoflurane/8% oxygen. Small bilateral
arthrotomies were used to generate three osteochondral
drill holes to 2 mm target depth in each femoral trochlea
using a 1.4 mm diameter round drill burr (Fine Sciences
Tools, Foster City, CA, USA) and a hand-held high speed
drill under irrigation with Ringer’s Lactated Saline. For
each rabbit, 3 mixtures were generated in distinct flat-
bottom cryovials as described above, using 125 μL of
150K, 40K or 10K chitosan solution (1.6% w/v chitosan/
150 mM NaCl solution), 12.5 μL 5 mg/mL RITC-chitosan
of matching molecular mass (see Table 1) and 0.75 mL
aseptic rabbit peripheral arterial liquid whole blood. 15 μL
of the liquid implant mixture was drawn into a M100 ster-
ile microman tip with the tapered end cut off. 3 μL of Tis-
sue Factor was deposited in a sterile petri dish and then
drawn into the same tip by back-screwing the microman
pipettor to stimulate coagulation and thus solidify the im-
plant inside the plastic microman tip (5 minutes at room
temperature). Solid implants were extruded onto a sterile
petri with labels, then each was press-fit into the 3 drill
holes of the left knee (150K proximal, 40K middle, and
10K distal hole), while right knee control drill holes were
left to bleed (N=2) or treated with 3 μL of Tissue Factor
(3 μL per hole, N=2). Knees were closed in three layers
using prolene 5–0 sutures, and buprenorphine was
administered post-operatively twice a day for at least 3
days. Macroscopic appearance of the knees and incisions,
body weight and signs of both pain and anorexia were
monitored daily from the surgery to the necropsy to assess
the health of the rabbits. There were no signs of knee in-
fection at necropsy. After 1 day (N=1) or 21 days (N=4)
post-surgery, the rabbits were euthanized under ketamine-
xylazine anesthesia by IV injection of sodium pentobar-
bital and the femoral ends were retrieved and fixed in 4%
paraformaldehyde/100mM cacodylate, pH 7.4. Fixed femur
ends were placed trochlea face-down in buffered saline in a
petri to acquire macroscopic fluorescent images of the
defects with an inverted epifluorescent microscope, digital
camera and calibrated histomorphometric software with a
controlled image acquisition time (Northern Eclipse,
Empix, Missisauga, ON, Canada).
Micro-computed tomography (Micro-CT)
Femur ends were trimmed of their condyles using a low-speed
isomet saw and scanned on a 180° axis using a SkyScan1172
high-resolution desktop X-ray microtomograph (Skyscan,
Kontich, Belgium) set to an image size of 2000 X 1048
pixels at pixel size resolution of 9.8 μm, 2-frame averagingand at 80 kV with an aluminum-copper filter. The data
sets were reconstructed in a 3D model using the NRecon
software (Skyscan, Kontich, Belgium) with smoothing = 2,
ring artifact correction = 4, beam hardening correction =
30%, object bigger than field of view = ON, output
range = 0.00 to 0.05. The reconstructed files were
blinded by a third party. Using the DataViewer soft-
ware (Skyscan, Kontich, Belgium), each drill hole was
re-positioned so that the y-axis ran vertically through
the hole depth. The correct vertical alignment was
then confirmed by two readers and the repositioned
dataset was cropped into a new file. The top of each
hole represented the osteochondral junction, visualized
in corresponding histological sections as the tidemark
of the calcified cartilage layer, and was defined as the most
superficial image slice on the aligned reconstructed scans
on which the bone completely surrounded the residual
drill hole edges. The bottom of the hole was defined as
the deepest axial slice that contained non-mineralized tis-
sue, while a constant and dense bone zone could be
observed at the base of the hole on both sagittal and cor-
onal planes. The hole depth was calculated as the number
of 2-D slices between the top and the bottom of the hole
and multiplied by the pixel size (9.8 μm per slice). The re-
sidual hole cross-sectional area (mm2) was quantified at
the top of the hole and at three different depths (0.5 mm,
1.0 mm and 1.5 mm) from the top of the hole using a
polygon tool (CTAn software, Skyscan, Kontich, Bel-
gium) to draw a 2D region of interest in the axial plane
that circumscribed the non-mineralized hole edge (Add-
itional file 1: Figure S1A). The signal inside the region of
interest was then processed using an inverted 70–0 gray-
scale threshold to exclude mineralized tissue and include
the non-mineralized drill hole cross-sectional area (Add-
itional file 1: Figure S1B, C), which was then computed by
the CTAn software.
Histoprocessing, histostaining and immunohistochemistry
Femoral ends were decalcified at 4°C in 10% (w/v)
ethylene diamine tetraacetic acid (EDTA)/0.1% (w/v)
paraformaldehyde/phosphate buffered saline pH 7.2.
25 serial sagittal cryosections of 10 μm thickness were
collected at the medial edge and through the middle of
the 3 drill holes with CryoJane tape (Instrumedics, St
Louis, MO, USA). Images of sections containing re-
sidual RITC-chitosan particles were generated with un-
stained and unmounted cryosections, by merging a
1.25x epifluorescence image with a low-intensity bright
field image of the same field. Residual chitosan implant
was measured by semiquantitative threshold analysis of
red fluorescent particles in 1.25x fluorescent images
acquired at a constant 400 ms exposure. Soft tissue in
each hole was cropped into a new image, thresholded
to a fixed value, and the total fluorescent area per hole
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middle of the holes and the values averaged (N=4).
Northern Eclipse software was used (Empix, Missis-
sauga, ON, Canada). Cryosections were stained with
Safranin O-fast green-iron hematoxylin, or immunostained
for collagen type I (col I) and collagen type II (col II),
following previously described methods [20], using anti-
human collagen type I antibody I-8H5 (MP Biomedicals,
Solon, OH, USA) at 10 μg/mL, anti-human collagen type
II hybridoma supernatant II6B3 (DSHB, Iowa City, IA,
USA) diluted 1:10 and biotinylated goat anti-mouse sec-
ondary antibody (B-7151; Sigma-Aldrich, Oakville, ON,
Canada) at 11 μg/mL. Specificity was confirmed by the ab-
sence of immunostaining by isotype-specific mouse anti-
sera or primary antibody omission.
Quantitative histomorphometry was carried out on
calibrated 40x digitally scanned slides and Northern
Eclipse V8.0 software (Empix Imaging, Inc., Missis-
sauga, ON, Canada). Percent tissue stained for GAG,
col I or col II was obtained by thresholding, and divid-
ing by the total soft repair tissue area per drill hole.
Histomorphometry of cross-sectional area (mm2) oc-
cupied by 4 granulation tissue types was carried out by
selective cropping and threshold analysis of tissues
from digital images of col I-immunostained sections
(middle and edge of the holes), using the following cri-
teria: (1) Apoptotic tissues contained mainly cells with
fragmented nuclei, nuclear debris, and few cells with
intact nuclei, (2) Neutrophil-rich tissues contained
neutrophils with lobed or round nuclei, few stromal
cells and low levels of apoptotic cells and nuclear deb-
ris, (3) Neutrophil+stromal tissues contained abundant
neutrophils and stromal cells with an elongated fibroblast-
like cell shape, (4) Stromal tissues were devoid of
neutrophils and contained abundant stromal cells. Un-
biased quantitative stereology for neutrophil and stromal
cell density was carried out on a representative 40x image
from each of the 4 tissue types in each treated defect
(N=4, middle of the hole), over which a 20 x 20 μm
grid, with 108 total points (Ptotal), was randomly
placed. All neutrophils or stromal cells touching the
grid intersections were counted (Vv = ΣPcell type/
ΣPtotal). A 100x picture of an apoptotic cell and a vi-
able neutrophil were also taken. Repair tissue integration
with the bone plate was analyzed in Safranin O, col I and
col II-stained sections by calibrated histomorphometry.
Line measures along the drill hole side-walls determined
the distance between the osteochondral junction, as
extrapolated from the tidemark in flanking cartilage-bone,
and the closest subchondral repair tissue that was
integrated to calcified cartilage or bone. Integration/de-
tachment was measured on both sides of each hole
and the mean value was retained. Cryosections were
enzymatically stained with tartrate-resistant acidicphosphatase (TRAP) to reveal osteoclasts as previ-
ously described [10] and counterstained in methyl
green (Vector Laboratories, Burlingame, CA, USA).
TRAP-stained sections were digitally scanned at 40x.
All large TRAP-positive cells adhering or adjacent to
bone with a rounded cell shape were defined as
osteoclasts [10] and were quantified in three different
depths from the defect surface: projected tidemark-0
.5 mm, 0.5 mm-1.0 mm and 1.0 mm-1.5mm, on both
sides of each hole. The GAG, col I and col II-positive
areas, as well as the osteoclast quantification, were
performed by two independent blinded readers with
consistent inter-reader results. Cryosections were also
stained with Gomori Trichrome solution using 0.6%
(w/v) Chromotrope 2R (C-3143, Sigma, Oakville, On-
tario, Canada), 0.3% (w/v) Fast Green and 0.6%
phosphotungstic acid (P-4006, Sigma, Oakville, On-
tario, Canada).
Statistical methods
The General Linear Model (GLM, Statistica version 9.0,
StatSoft, Tulsa, OK, USA) with Fisher LSD post hoc ana-
lysis to analyze univariate effects was used to test the ef-
fect of chitosan molecular mass (150K, 40K, 10K) and
defect position (proximal, mid, distal) after 21 days on
chitosan residency, percent GAG-positive area, percent
col I-positive area, percent col II-positive area, percent
apoptotic, neutrophil-rich, neutrophil+stromal and stro-
mal repair tissue area, neutrophil and stromal cell volume
density, detached repair tissue, number of osteoclasts in
three depth ranges, residual hole area at the top of the
hole and at three depths and residual hole depth (N=4).
Significance was set at p<0.05.
Results
In vitro pre-solidified chitosan/blood implant optimization
Optimization studies were carried out in vitro to select a
method to generate implants with homogeneously dis-
tributed chitosan particles that coagulated rapidly, which
could facilitate their use in a clinical setting. Sterile
chitosan solutions were successfully generated with high,
low, and ultra-low molecular mass chitosans, here
termed 150K, 40K, and 10K respectively (Table 1). Iso-
tonic chitosan/blood mixtures formed solid, cylindrical
elastic clots when incubated at 37°C in glass tubes, but
remained liquid when incubated in plastic tubes (unpub-
lished observations). These data were consistent with
previous studies showing that chitosan-GP/blood mix-
tures solidify via normal coagulation mechanisms
involving platelet and thrombin activation [11,21]. Pre-
solidified implants showed a homogeneous punctate
distribution of insoluble RITC-chitosan particles for
150K (Figure 1A, C), 40K (Figure 1B, D) and 10K (data not
shown). Coagulation in plastic tubes at room temperature
Figure 1 Chitosan/blood implants form solid, cylindrical hybrid
clots with punctate, insoluble RITC-chitosan particles distributed
homogenously. (A, B) 1.25x and (C, D) 5x magnification
epifluorescence pictures of chitosan-GP/blood (1:6 v/v ratio)
implants after solidification in glass tubes. (E) Solidification of the
implants in M100 microman pipet tips (arrows) using Tissue Factor,
and (F) solid chitosan-NaCl/blood implant (arrow), with some
extruded serum.
Figure 2 Chitosan-NaCl/blood implants reside in osteochondral
drill holes for 21 days post-operative. (A) Microdrilled defects in
rabbit trochlea. (B) Microdrilled defects in rabbit trochlea after press-fitting
3 pre-solidified implants (arrows). (C) Control defects after 1 day show a
blood clot inside the holes (the distal control defect was treated with
Tissue Factor). (D) Treated defects after 1 day show implants inside the
holes. (E) Control defects after 3 weeks are filled with a white fibrous or
fibrocartilage repair tissue. (F) Treated defects after 3 weeks are filled with
a mixture of red angiogenic granulation tissue and white granulation
tissue containing neutrophils or stromal cells. (G, H) 1.25x magnification
epifluorescence pictures with 200ms exposure of whole knee trochlea
shows three defects that retained RITC-chitosan after (G) 1 day and (H)
21 days.
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VIIa (rhFVIIa) to rabbit whole blood prior to mixing with
chitosan (unpublished observations), or addition of a small
volume of Tissue Factor (TF, Figure 1E). TF-chitosan
-NaCl/blood implants formed rapidly (5 minutes) and
retained a cylindrical shape after being extruded from the
tip, with some serum expressed (Figure 1F).In vivo implant residency, repair responses and tissue
characterization
Control drill defects were created in the femoral trochlea
and allowed to fill with trabecular bone-derived blood,
or treated with TF as a controlled variable (Figure 2A).
Treated drill defects were press-fit with each of three
distinct TF-chitosan-NaCl/blood implants with fluores-
cent chitosan tracer (150K, 40K, 10K) (Figure 2B). At 1
day post-operative, the microdrill holes were either filled
with blood clot (Figure 2C) or implant (Figure 2D). At 21
days post-operative, all control defects were filled with a
white repair tissue, while treated defects contained a mix-
ture of white and red granulation tissue (Figure 2E, F).
Macroscopically, RITC-chitosan was observed to be
confined to the drill holes after both 1 and 21 days, with a
fainter signal at 21 days (Figure 2G, H).Fluorescent chitosan particles underwent a dynamic
change in distribution in the repairing bone defects over
21 days of repair. At day 1, chitosan implants laterally
filled the upper portion of the drill holes (white arrows,
Figure 3A) and contained scarce leukocytes within densely
packed erythrocytes (Figure 3B). At 21 days post-operative,
residual chitosan particles were dispersed unevenly
throughout the holes and infiltrated with many neutrophils
(Figure 3C-F). High molecular weight chitosan tended
to clear more slowly from the defects compared to
low molecular weight chitosan, as evidenced by the
larger area of residual 150K chitosan compared to
10K chitosan in the middle of the holes (p=0.12, N=4,
Figure 3F). Persistence of chitosan in all drill holes was
associated with neutrophil chemotaxis, and delayed
Figure 3 Chitosan/blood implants reside near the top of the drill holes and elicit neutrophil chemotaxis. (A, C) 1.25x magnification
epifluorescence pictures of unstained sagittal cryosections taken in the middle of the holes, merged with bright field pictures to show the tissues.
(C, D) 1.25x magnification pictures of collagen type I-immunostained serial sagittal sections adjacent to those shown in (A) and (B). Panel (A)
shows that RITC-chitosan particles in all 3 implants at day 1 are laterally filling the top half of the defects (red stain above white arrows). Panel (C)
shows that RITC-chitosan particles persist with residual implant after 21 days in vivo and co-localize with areas of high-density neutrophils, as
shown in (D). (E, F) Total RITC-fluorescent area of each treated hole at 21 days post-operative (N=4) as taken from 1.25x magnification
epifluorescence pictures of unstained cryosections taken at the edge of the hole (E) or in the middle of the hole (F). (mean ± standard
deviation). In the middle of the hole, 150K chitosan particles tended to reside longer in the defects than 10K chitosan particles (p=0.12, F).
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http://www.biomedcentral.com/1471-2474/14/27accumulation of col I, col II and glycosaminoglycans (GAG)
in the soft repair tissues (Figure 4A-F).
At 3 weeks post-operative, treated defects were mainly
composed of granulation tissue (Figure 4D-F), whereas
the blood clot initially formed in control bone defects
was replaced by a variable mixture of GAG-depleted col
I+/col II+ chondral repair tissues and GAG-rich, col I
+/col II+ subchondral repair tissues (Figure 4G-L). Soft
repair tissues formed in treated drill holes contained sig-
nificantly less collagen type I (p<0.001), collagen type II
(p<0.01) and GAG (p<0.01) than matching control
defects (N=4; Figure 5).
Four types of granulation tissue were observed in treated
defects: apoptotic, neutrophil-rich, neutrophil+stromal
and stromal (Figure 6A-F). A core of apoptotic tissue
characterized the granulation tissue of 150K-treated
defects, that covered a larger area than both 40K and
10K-treated defects (p=0.0417, p=0.0515, respectively,Figure 7A, B). From the periphery of apoptotic tissues
to the edges of the holes, decreasing neutrophil counts
and increasing levels of stromal cells were observed
(Figure 7C). Control drill holes had a more advanced
wound repair, and were mainly filled with collagen type I,
interspersed with collagen type II and GAG (Figures 4–5).
Above the osteochondral junction, control repair tissues
contained numerous fibrochondrocytes and fibroblasts
embedded in a collagen type I matrix (Figure 6I, K), while
subchondral control tissues below the osteochondral junc-
tion were populated with fibrous tissue, chondrocytes and
hypertrophic chondrocytes (Figure 6J, L). A local fibro-
plasia was also reproducibly observed in the metaphyseal
marrow below the proximal control drill holes and prox-
imal 150K-treated defects (Figure 4 F, L; black arrows).
Neutrophil migration to the implants in treated defects
was accompanied by osteoclast chemotaxis to the bone
plate region of all three chitosan formulations (Figure 8,
Figure 4 Treated defects exhibit delayed collagen matrix deposition and strong neutrophil chemotaxis. Representative 1.25x
magnification pictures from serial sagittal sections taken in the middle of the holes in the same rabbit knee showing treated defects after (A-C)
1 day (N=1) and (D-F) 21 days (N=4), and control defects after (G-I) 1 day (N=1) and (J-L) 21 days (N=4). Panels show collagen type I-positive,
collagen type II-positive, and Safranin O-stained glycosaminoglycan tissues. White arrowheads: neutrophil-rich granulation tissue, black arrows:
local fibroplasia in bone marrow below the proximal drill holes.
Lafantaisie-Favreau et al. BMC Musculoskeletal Disorders 2013, 14:27 Page 8 of 16
http://www.biomedcentral.com/1471-2474/14/27Figure 9A). The bone plate region of treated drill holes
(i.e., the tidemark to 0.5 mm deep), contained 10-fold
more TRAP+ osteoclasts and osteoclast precursors on
the defect edges compared to controls (Figure 8; p<0.01,
N=4, Figure 9A). Deeper in the holes, treated defects
contained similar or lower levels of TRAP+ osteoclasts
and osteoclast precursors than controls (Figure 9A).Figure 5 Treated defects 21 days post-treatment contain less GAG, co
in each drill hole cross-section in cryosections taken in the middle of the h
Safranin O-stained glycosaminoglycan, at 21 days (N=4) post-treatment. (mInitial defects by quantitative micro-CT analysis had a
uniform ~1.6 mm diameter and 2.3 mm deep shape
(N=6, Figure 9B-C). All implants induced bone resorp-
tion, which lead to tear drop-shaped bone defects at 3
weeks post-operative, as opposed to no appreciable
change in control defect dimensions (Figure 9B-C).
Compared to initial and control defects, all treatedl II and col I than controls. Percent of the soft repair tissue present
oles containing (A) collagen type I, (B) collagen type II, and (C)
ean ± standard deviation). **p<0.005, ***p<0.0005.
Figure 6 Granulation tissues in treated defects versus chondral/subchondral tissues in control defects at 21 days post-operative. Panels
show collagen type I-immunostained/iron hematoxylin counterstained histology images at 1.25x (A-B, G-H) and 40x magnification (C-F, I-L). (A-F)
Treated repair tissues from representative 150K and 10K-treated defects contained apoptotic (a), neutrophil-rich (n), neutrophil+stromal (ns) and
stromal (s) tissues. Control tissues from representative proximal and distal defects contained fibrochondrocytes (fc) above the osteochondral junction
(I, K), and subchondral chondrocytes (sc) or hypertrophic chondrocytes (htc) below the osteochondral junction (J, L). At the articulating surface of the
control defects, fibrochondrocytes and are identified by strong collagen type 1 expression and flattened morphology.
Lafantaisie-Favreau et al. BMC Musculoskeletal Disorders 2013, 14:27 Page 9 of 16
http://www.biomedcentral.com/1471-2474/14/27defects showed a ~2-fold increase in hole area at the calci-
fied cartilage/bone plate (p<0.001), and ~3-fold wider hole
area at deeper levels (p<0.001 vs controls, Figure 9B). By
micro-CT, high molecular weight chitosan induced a par-
ticularly strong bone resorption at 0.5mm and 1.5mm
depths (p<0.05, 150K vs 40K hole area, Figure 9B), which
was consistent with histomorphometry measures in colla-
gen type I-stained sections showing a larger area of granu-
lation tissue in 150K-treated defects than in both 40K and
10K-treated defects after 21 days (p<0.05, data not shown).
Micro-CT analysis of hole depth also showed that middle
control bone defects were significantly shallower than the
40K-treated middle hole (p<0.05, Figure 9C).
The strong resorption in treated defects was accom-
panied by the synthesis of new woven bone and angio-
genesis (Figure 10). Although the treated holes were bigger
than the initial 2 mm deep, 1.4 mm diameter drill holes
(Figure 9B, Figure 10A), subchondral new woven bone was
identified by characteristic high-density osteocytes with a largercell diameter compared to small osteocytes in peripheral non-
remodeled trabecular bone (Figure 10B). Blood vessels were
detected in the granulation tissue of treated defects
(Figure 10B). The synthesis of new woven bone
demonstrates that the implant has induced remodeling
and not exclusively osteoclastic resorption. In control
defects, no signs of bone resorption were present
(Figure 9B, Figure 10D) and the subchondral bone
contained large blood vessels, low levels of new woven
bone, as chondrocytes fused to bone (Figure 10E) which
indicates that endochondral ossification is underway.
Osteoclast-induced bone remodeling in the bone plate
area of treated defects was associated with a 10-fold greater
lateral integration of treated repair tissues with the bone
plate compared to control defects with detached repair
(p<0.05, Figures 11 and 12). The mean lateral detachment
was <35 μm deep in treated holes versus ~350 μm deep in
control drill holes in sections immunostained for colla-
gen type II (Figure 11A-C, Figure 12), collagen type I
Figure 7 Distribution of repair tissues in treated defects and
volume density of neutrophils and stromal cells. Relative cross-
sectional area of apoptotic, neutrophil-rich, neutrophil+stromal and
stromal tissues in sections collected (A) at the edge and (B) through
the middle of treated defects in collagen type I-stained cryosections
(N=4). Apoptotic tissues cover a larger area in the middle of 150K-
treated defects after 21 days than 40K and 10K-treated defects
(p=0.0417, p=0.0515, respectively). (C) Volume density (Vv) of
neutrophils and stromal cells in 40x magnification pictures of
neutrophil-rich, neutrophil+stromal and stromal tissues in the middle
of day 21 treated defects of collagen type I-stained
cryosections (N=4).
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http://www.biomedcentral.com/1471-2474/14/27(Figure 11D-F), and stained for Safranin O (Figure 4L).
Given that the bone plate (including the calcified car-
tilage) is ~400 μm thick in skeletally mature rabbits
[23,24], these data showed that the marrow-derived
fibrocartilage repair in control defects was generally
not integrated with the bone plate. All three chitosan
formulations reproducibly induced the same improved
level of bone repair tissue integration.Discussion
This study demonstrated that subchondral chitosan
implants sequentially draw neutrophils and undifferenti-
ated bone marrow-derived stromal cells into drilled bone
defects, which was accompanied by osteoclast formation
and bone remodeling. Neutrophil attraction and bone
resorption increased in proportion to higher chitosan
molecular mass. After 3 weeks of repair, all chitosan
implants induced neutrophil chemotaxis, stromal cell re-
cruitment, delayed extracellular matrix deposition, and
enhanced osteoclast-driven subchondral bone remodel-
ing. Although both subchondral bone resorption and the
synthesis of new woven bone were observed, the resorp-
tion was definitively stronger during the first three
weeks of repair, as evidenced by the larger size of the
treated holes compared to acute defects. At day 21,
osteoclast recruitment below the bone plate was similar
in both treated and control defects, which suggests a
shift towards woven bone repair in treated defects after
21 days (Figure 10). Our data confirm the hypothesis
that subchondral chitosan implants attract more bone
marrow stromal cells than control defects in a time-
delayed manner. Our data do not support the hypothesis
that the implants are cleared with similar kinetics as the
blood clot, given that chitosan particles still persisted at
3 weeks in the drill holes.
Biodegradable chitosan is known to elicit neutrophils via a
leukotriene B4-sensitive pathway, while promoting an anti-
inflammatory phenotype as chitosan-stimulated neutrophils
release neither superoxide nor myeloperoxidase [25]. Pre-
vious chitosan-induced cartilage repair studies in rabbits
have documented neutrophil chemotaxis at 21 days that is
associated with a delay in matrix deposition, as observed
in the current study [9,26]. The benefits of delayed matrix
deposition after three weeks was also demonstrated in
defects treated with PLG subchondral implants in rabbits,
although implant clearance was not specifically reported
and evidence of neutrophil or osteoclast attraction was
not shown [3,27]. Most importantly, in a separate study,
10K pre-solidified chitosan-NaCl/blood implants elicited
hyaline-like cartilage repair tissue and delayed callus for-
mation compared to drill-only defects after 2.5 months in
skeletally aged rabbits [28]. The more potent wound repair
response to subchondral chitosan implants may therefore
be the key to eliciting therapeutic marrow-stimulation re-
pair tissues in aged subjects.
Although wound healing benefits from an early influx
of neutrophils, failure to clear apoptotic neutrophils can
cause impaired tissue repair [29,30], which could render
the subchondral chitosan implant reactions problematic
when scaling-up the implant to enhance marrow stimu-
lation in patients. Efferocytosis, the uptake of apoptotic
cells by macrophages [31], is a natural process in the
resolution of inflammation. The low levels of apoptotic
Figure 8 Treated defects elicit osteoclast chemotaxis to the bone plate and subchondral bone remodeling. Representative TRAP-stained
decalcified sagittal sections at 1.25x (A, D, G) and 40x magnifications (B, E, H). (A, B) No osteoclasts were present in day 1 defects. (D, E) In
treated defects after 21 days, numerous osteoclasts have migrated to the subchondral bone plate. (G, H). In control defects after 21 days, many
osteoclasts have formed deeper in the repairing bone defect, but not at the subchondral bone plate level. (C, F, I) 2D-micro-CT images of
mineralized tissue in matching sagittal sections show strong subchondral bone remodeling in treated defects, in contrast with the control defects
with negligible remodeling of the hole sidewalls. Symbols: AC, Cartilage; B, Bone; I, Implant; RI, Residual implant; RT, Repair tissue.
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150K-treated defects, suggest efficient efferocytosis by
local macrophages that prevents triggering a foreign
body response. The lower levels of residual apoptotic
cells in the defects treated with low molecular weightFigure 9 Depth-wise measures of osteoclast chemotaxis and quantific
of TRAP+ cells lining both sides of each hole were quantified in three segm
(0.5-1.0 mm deep) and deeper level (1.0-1.5mm deep). Compared to contro
in the bone plate region 21 days post-treatment (N=4). (B) Hole cross-secti
1.5 mm depth) in 3D microCT reconstructed scans in defects from 1 day (N
larger, and bone remodeling was particularly strong in 150K-treated defect
days. (C) Depth of the drill holes in micro-CT scans showed that middle co
base than the matching 40K-treated defects. (mean ± standard deviation).chitosan (Figure 7B) correlate with sparse resident
chitosan particles in the current study and a more rapid
cell-based clearance of the smaller chitosan polymer
chains, as previously documented [32]. Efferocytotic
macrophages also secrete transforming growth factor-βation of non-mineralized bone hole dimensions. (A) Total number
ents of each hole: the bone plate (tidemark-0.5mm deep), mid-level
ls, treated defects showed more osteoclasts and osteoclast precursors
onal area at four depths (tidemark, 0.5 mm depth, 1.0 mm depth and
=1) or 21 days (N=4) post-treatment. Treated drill holes became
s at 0.5 mm and 1.5 mm depths compared to 40K-treated after 21
ntrol holes, after 21 days (N=4), were significantly more repaired at the
*p<0.05, **, ††p<0.01, ***, ###p<0.001.
Figure 10 Bone resorption and repair in chitosan-treated defects (A-C) versus minor endochondral bone repair in controls (D-F).
Gomori Trichrome-stained sagittal cryosections of (A, B) a 10K-treated defect and (D, E) a distal control defect and matching Safranin O-fast
green-stained section (C, 10K-treated defect; F, control defect). Symbols: Vertical bar: initial defect 2 mm depth; black arrows: zone of previous
bone resorption (thick arrow) and woven bone repair (thin arrow); black arrowhead: blood vessels; white arrowhead: new woven bone; star:
bone-induced chondroinduction [12,22].
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http://www.biomedcentral.com/1471-2474/14/27[33,34], a key cytokine in wound healing [35], as well as
the anti-inflammatory factor interleukin-10 [36], which
further emphasizes the importance of proper neutrophil
clearance in scaffold-guided osteochondral repair. While
the areas in all defects that were characterized by high
levels of neutrophils (viable or apoptotic) contained few stro-
mal cells and no collagen type I, they were directly bordered
by tissues rich with stromal cells (Vvstromal = 0.17), at levels
similar to that previously reported at 3 weeks post-operative
in microdrill defects overlayed with chitosan-GP/blood im-
plant (Vvstromal = ~0.15) [9]. Stromal cells were thus recruited
to the periphery of treated defects but only following timely
neutrophil clearance; the sustained but more controlled neu-
trophil response for 40K and 10K implants therefore predicts
a more therapeutic response at a later period in the rabbit
model. This prediction is consistent with the outcome of a
separate mid-term study in skeletally aged rabbits, in which
10K pre-solidified chitosan-NaCl/blood implants elicited a
more hyaline repair tissue compared to 40K implant and un-
treated control drill holes [37].
Enhanced bone resorption correlated with the accu-
mulation of neutrophils in treated defects compared to
controls. The larger soft tissue area in 150K-treated
defects also supports a relationship between prior neu-
trophil recruitment (i.e., apoptotic neutrophils present at
3 weeks in 150K-treated defects) and prior osteoclast ac-
tivity. Receptor activator of NF-κB ligand (RANKL)induces the differentiation of osteoclast precursors
[38,39]. In synovial fluid-derived neutrophils from
patients with rheumatoid arthritis, as well as in blood-
derived neutrophils stimulated with lipopolysaccharide
and granulocyte macrophage colony-stimulating factor,
RANKL is expressed and mediates bone resorption and
osteoclastogenesis in vitro [40]. RANKL is also chemo-
tactic for human monocytes [41,42]. Additionally, mono-
cyte chemoattractant protein 1 (MCP-1/CCL2) and
interleukin-8 (IL-8/CXCL8), are released from leukocytes
within chitosan/blood clots and whole blood clots [26].
At the wound site, these chemokines could continue to
be released from extravasated neutrophils [43] and endo-
thelial cells through neutrophil mediators such as
proteinase-3 [44,45]. In other studies, these chemokines
stimulated osteoclast differentiation of human bone
marrow mononuclear cells [46] and rat osteoclast
precursor cells [47]. The local release of RANKL,
MCP-1/CCL2 and IL-8/CXCL8 could thus polarize
elicited macrophages to differentiate into osteoclasts in
the drill hole. Interestingly, MCP-1/CCL2 could also have
a role in neutrophil clearance, as it enhances efferocytosis
[48]. Osteoclast formation promoted by “topical”
chitosan-blood implants solidified over drill holes was pre-
viously tied to bone remodeling and improved repair tis-
sue integration [10], as well as a more hyaline repair tissue
at 8 weeks post-operative [9,11]. Osteoclast recruitment is
Figure 11 Treated defects show better lateral repair tissue integration with the bone plate than control defects. Panels (A-C, G-I) show
collagen type II-stained sections and Panels (D-F, J-L) show collagen type I-stained sagittal sections from control defects (A-F) and treated
defects (G-L) 21 days post-treatment). Symbols: AC: Articular cartilage; Black arrows: Detached repair tissue; White arrowheads: neutrophil-rich
granulation tissue.
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http://www.biomedcentral.com/1471-2474/14/27also closely related to angiogenesis [49,50] and osteo-
clast conditioned media has a chemotactic effect on
mesenchymal stem cells [51]. Osteoclast-dependant
bone resorption could therefore enhance migration of
mesenchymal stem cells to the bone plate region,
which could be a key event in the cartilage repair
properties of chitosan that is indirectly related toFigure 12 Average detached repair tissue at the bone plate is
greater in control than in treated defects. Collagen-type II-stained
sections in the middle of the holes, 21 days post-treatment. (mean ±
standard deviation, N=4). #,†p<0.05. **p<0.01.neutrophil recruitment. Stem cell recruitment could
hold an especially important role in the treatment of
cartilage defects in older patients who tend to be es-
pecially susceptible to microfracture failure [13,14].
Altogether, data in this study shows that pre-solidified
chitosan-NaCl/blood implants can elicit osteoclasts to
the subchondral bone plate, most probably through a
neutrophil recruitment phase, and that molecular
weight of the polymer can be used to adjust the po-
tency of the bone remodeling response.
Development of chitosan-blood implants pre-solidified
ex vivo provides a novel strategy for delivering specific
dosages of low molecular weight chitosan (10K and 40K)
with low viscosity [52] to marrow stimulation defects.
Tissue Factor generated rapid implants which projects
to be more convenient in a clinical setting, although
InnovinW is not currently available as a pharmaceutical-
grade reagent. Clinical use of InnovinW in dental sinus
bone-augmentation procedures has been documented
[53]. In this study, no apparent differences were observed
between control defects left to bleed or administered with
TF, although in a sheep model, subchondral TF implants
were found to elicit sporadic bone plate resorption [Bell
et al., unpublished data]. Future studies are needed to
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clearance in marrow stimulation repair.
Chitosan-NaCl/blood pre-solidified subchondral implants
elicited highly reproducible and distinct biological responses
compared to controls. The statistically significant responses
to implant compared to the controls is quite remarkable
considering the low number of rabbits used (N=4). In the
context of formulation screening, the current study also
permitted the observation of greater neutrophil chemo-
taxis and bone resorption associated with slower clearance
of 150K implants compared to 10K and 40K. These
observations suggest that subchondral high molecular
weight chitosan implants are at risk for the development
of cysts at longer timepoints in the rabbit model, while
low molecular weight chitosan implants have a greater po-
tential for eliciting a delayed and improved osteochondral
repair. The use of only one rabbit at day 1 was sufficient
to document acute implant residency (Figures 2–3), and
to document very uniform initial defect dimensions
(Figure 9B-C), but did not permit any statistical compari-
son with day 21 defects. It is possible that proximo-distal
effects on repair were present, as only the proximal holes
showed fibroplasias in the deeper marrow. Such acute
alterations in the deep marrow are likely to be transient
given that adipocyte conversion in trabecular bone mar-
row is seen after 3 to 6 months post-operative below
rabbit drilled defects [54,55]. The close proximity of the 3
drill holes in one trochlea may have biased the molecular
mass-dependant repair reaction to the implants by those
in the adjacent hole, although the study still permitted the
observation of molecular weight-specific clearance and in-
duction of neutrophil chemotaxis and bone resorption.
These data have led us to change the model for mid-term
repair responses by using only two drill holes per trochlea
and further investigating the use of low molecular weight
chitosan.
Conclusions
This study has demonstrated that pre-solidified TF-
chitosan-NaCl/blood implants can be successfully retained
in microdrill holes, become partly cleared, and elicit
neutrophils followed by bone marrow-derived stromal
cells at 21 days in a skeletally aged rabbit model of cartil-
age repair. Three chitosan implant formulations reprodu-
cibly elicited neutrophils which guided osteoclasts to
the bone plate, delayed deposition of collagen and
glycosaminoglycan, induced subchondral bone resorp-
tion and repair and improved integration of the repair
tissue with the subchondral bone. In contrast, in con-
trol defects, osteoclasts did not migrate to the bone
plate, bone remodeling was limited to new woven bone
at the base of the hole and stromal cells that migrated
into the control drill holes promptly differentiated into
chondrocytes and fibroblasts (col I-rich fibrocartilage).This study also showed that the level of neutrophil
chemotaxis and osteoclast resorption was propor-
tional to chitosan molecular weight. The successful
characterization of the early, molecular weight-specific re-
pair responses to osteochondral implants in aged rabbits
constitutes a foundation for the elucidation of the molecu-
lar and cellular mechanisms of chitosan-guided neutro-
phil, stromal cell and osteoclast recruitment to marrow
stimulation defects, as well as the further investigation of
the cartilage repair properties of these implants at longer
timepoints.
Additional file
Additional file 1: Figure S1. Micro-CT inverted thresholding method for
quantification of residual (unrepaired) subchondral drill hole cross-sectional
area. (A, B) An axial 2-D image of a residual drill hole in a reconstructed micro-
CT data set in which a region of interest (excludes green area, includes black/
white area) was drawn at the edge of the hole. (A) Original 70–255
thresholded binary image (white: bone, black: non-mineralized tissue) and
(B) inverted 70–0 thresholded binary image (white: non-mineralized tissue,
black: bone). (C) After cropping with the inverted 70–0 threshold, the residual
hole cross-sectional area inside the region of interest is obtained through the
calibrated micro-CT software.
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